Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Testosterone + anastrozole is a combination therapy involving the administration of exogenous testosterone (a naturally occurring androgen hormone) and anastrozole, a non-steroidal aromatase inhibitor. Testosterone is used to treat male hypogonadism and other conditions associated with low testosterone levels. Anastrozole inhibits the aromatase enzyme, which converts testosterone to estradiol (an estrogen), thereby reducing circulating estrogen levels. This combination is primarily used off-label in men undergoing testosterone replacement therapy (TRT) who develop elevated estradiol levels or symptoms of estrogen excess, such as gynecomastia or fluid retention. By inhibiting aromatization, anastrozole helps maintain a favorable testosterone-to-estradiol ratio and may improve hormonal balance, fertility parameters, and clinical outcomes in certain populations[2][3][5]. The use of this combination should be monitored by healthcare professionals due to potential side effects including changes in bone mineral density and cardiovascular risk[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Testosterone + anastrozole.